Abstract
Defects in the biogenesis of peroxisomes cause a clinically and genetically heterogeneous group of neurometabolic disorders, the Zellweger syndrome spectrum (ZSS). Diagnosis predominantly is based on characteristic clinical symptoms, a typical biochemical profile, as well as on identification of the molecular defect in any of the 12 known human PEX genes. The diagnostic workup can be hindered if the typical clinical symptoms are missing and predicting the clinical course of a given patient is almost unfeasible. As a safe and noninvasive method to analyze specific chemical compounds in localized brain regions, in vivo proton magnetic resonance spectroscopy (MRS) can provide an indication in this diagnostic process and may help predict the clinical course. However, to date, there are very few reports on this topic. In this study, we performed localized in vivo proton MRS without confounding contributions from T1- and T2-relaxation effects at 2 Tesla in a comparably large group of seven ZSS patients. Patients’ absolute metabolite concentrations in cortical gray matter, white matter, and basal ganglia were assessed and compared with age-matched control values. Our results confirm and extend knowledge about in vivo MRS findings in ZSS patients. Besides affirmation of nonspecific reduction of N-acetylaspartate + N-acetylaspartylglutamate (tNAA) in combination with lipid accumulation as a diagnostic hint for this disease group, the amount of tNAA loss seems to reflect disease burden and may prove to be of prognostic value regarding the clinical course of an already diagnosed patient.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barkovich AJ, Peck WW (1997) MR of Zellweger syndrome. AJNR Am J Neuroradiol 18(6):1163–1170
Bowen P, Lee CS, Zellweger H, Lindenberg R (1964) A familial syndrome of multiple congenital defects. Bull Johns Hopkins Hosp 114:402–414
Bruhn H, Kruse B, Korenke GC et al (1992) Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders. J Comput Assist Tomogr 16(3):335–344
Detre JA, Wang ZY, Bogdan AR et al (1991) Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol 29(2):218–221
Dreha-Kulaczewski SF, Dechent P, Finsterbusch J et al (2008) Early reduction of total N-acetyl-aspartate-compounds in patients with vanishing white matter disease. A long-term follow-up MRS study. Pediatr Res 63(4):444–449
Dreha-Kulaczewski SF, Helms G, Dechent P, Hofer S, Gartner J, Frahm J (2009) Serial proton MR spectroscopy and diffusion tensor imaging in infantile Balo’s concentric sclerosis. Neuroradiology 51(2):113–121
Ebberink MS, Mooijer PA, Gootjes J, Koster J, Wanders RJ, Waterham HR (2011) Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat 32(1):59–69
Engelbrecht V, Rassek M, Huismann J, Wendel U (1997) MR and proton MR spectroscopy of the brain in hyperhomocysteinemia caused by methylenetetrahydrofolate reductase deficiency. Am J Neuroradiol 18(3):536–539
Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Hänicke W (1990) Improvements in localized proton NMR spectroscopy of human brain. Water suppression, short echo times, and 1 ml resolution. J Magn Reson (1969) 90(3):464–473
Grodd W, Krageloh-Mann I, Klose U, Sauter R (1991) Metabolic and destructive brain disorders in children: findings with localized proton MR spectroscopy. Radiology 181(1):173–181
Groenendaal F, Bianchi MC, Battini R et al (2001) Proton magnetic resonance spectroscopy (1H-MRS) of the cerebrum in two young infants with Zellweger syndrome. Neuropediatrics 32(1):23–27
Krause C, Rosewich H, Gartner J (2009) Rational diagnostic strategy for Zellweger syndrome spectrum patients. Eur J Hum Genet 17(6):741–748
Kruse B, Hanefeld F, Christen HJ et al (1993) Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol 241(2):68–74
Kuesel AC, Donnelly SM, Halliday W, Sutherland GR, Smith IC (1994a) Mobile lipids and metabolic heterogeneity of brain tumours as detectable by ex vivo 1H MR spectroscopy. NMR Biomed 7(4):172–180
Kuesel AC, Sutherland GR, Halliday W, Smith IC (1994b) 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 7(3):149–155
Miyanomae Y, Ochi M, Yoshioka H et al (1995) Cerebral MRI and spectroscopy in Sjogren-Larsson syndrome: case report. Neuroradiology 37(3):225–228
Nakayama M, Tavora DG, Alvim TC, Araujo AC, Gama RL (2006) MRI and 1H-MRS findings of three patients with Sjogren-Larsson syndrome. Arq Neuropsiquiatr 64(2B):398–401
Nelson SJ (2003) Multivoxel magnetic resonance spectroscopy of brain Tumors1. Mol Cancer Ther 2(5):497–507
Norfray JF, Tomita T, Byrd SE, Ross BD, Berger PA, Miller RS (1999) Clinical impact of MR spectroscopy when MR imaging is indeterminate for pediatric brain tumors. Am J Roentgenol 173(1):119–125
Poll-The BT, Gootjes J, Duran M et al (2004) Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients. Am J Med Genet A 126(4):333–338
Pouwels PJ, Brockmann K, Kruse B et al (1999) Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatr Res 46(4):474–485
Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30(6):672–679
Rosewich H, Ohlenbusch A, Gartner J (2005) Genetic and clinical aspects of Zellweger spectrum patients with PEX1 mutations. J Med Genet 42(9):e58
Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW (2006) Peroxisome biogenesis disorders. Biochim Biophys Acta 1763(12):1733–1748
Sylvain M, Arnold DL, Scriver CR, Schreiber R, Shevell MI (1994) Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin. Pediatr Neurol 10(3):228–232
Thoms S, Gronborg S, Rabenau J, Ohlenbusch A, Rosewich H, Gartner J (2011) Characterization of two common 5’ polymorphisms in PEX1 and correlation to survival in PEX1 peroxisome biogenesis disorder patients. BMC Med Genet 12:109
van der Knaap MS, Wassmer E, Wolf NI, Ferreira P, Topçu M, Wanders RJ, Waterham HR, Ferdinandusse S (2012) MRI as diagnostic tool in early-onset peroxisomal disorders. Neurology 78(17):1304–1308. doi:10.1212/WNL.0b013e31825182dc
van der Knaap MS, Valk J (1991) The MR spectrum of peroxisomal disorders. Neuroradiology 33(1):30–37
Wanders RJ (2004) Metabolic and molecular basis of peroxisomal disorders: a review. Am J Med Genet A 126(4):355–375
Wattjes MP, Harzheim M, Lutterbey GG, Klotz L, Schild HH, Träber F (2007) Axonal Damage But No Increased Glial Cell Activity in the Normal-Appearing White Matter of Patients with Clinically Isolated Syndromes Suggestive of Multiple Sclerosis Using High-Field Magnetic Resonance Spectroscopy. Am J Neuroradiol 28(8):1517–1522
Weller S, Rosewich H, Gartner J (2008) Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients. J Inherit Metab Dis 31(2):270–280
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Informed consent
The study was in accordance with the ethical standards of the institutional committee on human experimentation and with the Declaration of Helsinki, 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Additional information
Communicated by: Robert Steiner
H. Rosewich and P. Dechent contributed equally to this work.
Rights and permissions
About this article
Cite this article
Rosewich, H., Dechent, P., Krause, C. et al. Diagnostic and prognostic value of in vivo proton MR spectroscopy for Zellweger syndrome spectrum patients. J Inherit Metab Dis 39, 869–876 (2016). https://doi.org/10.1007/s10545-016-9965-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-016-9965-6